Wisconsin Capital Management LLC Has $7.05 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Wisconsin Capital Management LLC cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.9% during the fourth quarter, Holdings Channel reports. The firm owned 68,135 shares of the company’s stock after selling 643 shares during the quarter. Novo Nordisk A/S makes up 4.2% of Wisconsin Capital Management LLC’s portfolio, making the stock its 7th biggest holding. Wisconsin Capital Management LLC’s holdings in Novo Nordisk A/S were worth $7,049,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. CNB Bank purchased a new position in Novo Nordisk A/S in the 4th quarter worth approximately $26,000. Pacific Center for Financial Services boosted its position in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the last quarter. Valued Wealth Advisors LLC bought a new stake in Novo Nordisk A/S in the fourth quarter worth $28,000. Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 100.0% in the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after buying an additional 141 shares during the last quarter. Finally, Bell Investment Advisors Inc lifted its position in Novo Nordisk A/S by 79.9% in the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 0.3 %

NVO stock traded down $0.36 during mid-day trading on Thursday, reaching $125.80. The company had a trading volume of 3,431,971 shares, compared to its average volume of 4,816,638. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The company has a market capitalization of $564.53 billion, a price-to-earnings ratio of 46.51, a price-to-earnings-growth ratio of 2.15 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The firm has a fifty day simple moving average of $126.80 and a 200 day simple moving average of $111.74.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The firm had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a $0.664 dividend. The ex-dividend date of this dividend was Friday, March 22nd. This represents a dividend yield of 0.9%. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is currently 49.17%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on NVO shares. BMO Capital Markets started coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Finally, UBS Group started coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.